A randomized, double-blind, placebo-controlled, phase 2b Study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation

• Main Authors: Jean Louis Vincent, Mayakonda K. Ramesh, David Ernest, Steven P. Larosa, Jan Pachl, Naoki Aikawa, Eric Hoste, Howard Levy, Joe Hirman, Marcel Levi, Mradul Daga, Demetrios J. Kutsogiannis, Mark Crowther, Gordon R. Bernard, Jacques Devriendt, Joan Vidal Puigserver, Daniel U. Blanzaco, Charles T. Esmon, Joseph E. Parrillo, Louis Guzzi, Seton J. Henderson, Chaicharn Pothirat, Parthiv Mehta, Jawed Fareed, Deepak Talwar, Kazuhisa Tsuruta, Kenneth J. Gorelick, Yutaka Osawa, Inder Kaul
• 格式: 雜誌
• 出版: 2018
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84883615933&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/47693

Objectives:: To determine the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with suspected sepsis-associated disseminated intravascular coagulation. design:: Phase 2b, international, multicenter, double-blind, randomized, placebo-controlled, parallel group, screening trial....